Jane Street’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54.9M Buy
122,946
+111,700
+993% +$52.1M 0.01% 990
2025
Q4
$5.1M Sell
11,246
-237,021
-95% -$102M ﹤0.01% 3197
2025
Q3
$97.2M Buy
+248,267
New +$104M 0.01% 611
2025
Q2
Sell
-15,008
Closed -$6.92M 11028
2025
Q1
$7.28M Buy
15,008
+454
+3% +$212K ﹤0.01% 2393
2024
Q4
$5.86M Sell
14,554
-39,638
-73% -$18.4M ﹤0.01% 2466
2024
Q3
$25.2M Sell
54,192
-249,474
-82% -$120M 0.01% 1070
2024
Q2
$142M Buy
303,666
+161,058
+113% +$69.9M 0.03% 286
2024
Q1
$59.6M Sell
142,608
-31,151
-18% -$13.2M 0.01% 548
2023
Q4
$70.7M Buy
173,759
+113,416
+188% +$41.9M 0.02% 528
2023
Q3
$21M Buy
60,343
+31,869
+112% +$11.1M 0.01% 1061
2023
Q2
$10M Buy
28,474
+6,735
+31% +$2.27M ﹤0.01% 1898
2023
Q1
$6.85M Sell
21,739
-1,290
-6% -$387K ﹤0.01% 2045
2022
Q4
$6.65M Sell
23,029
-10,017
-30% -$3.05M ﹤0.01% 2115
2022
Q3
$9.57M Buy
33,046
+10,370
+46% +$2.98M ﹤0.01% 1741
2022
Q2
$6.39M Buy
22,676
+5,752
+34% +$1.54M ﹤0.01% 2311
2022
Q1
$4.42M Sell
16,924
-49,144
-74% -$11.7M ﹤0.01% 3247
2021
Q4
$14.5M Sell
66,068
-69,179
-51% -$13.5M ﹤0.01% 1474
2021
Q3
$24.5M Sell
135,247
-39,047
-22% -$7.62M 0.01% 1000
2021
Q2
$35.1M Buy
174,294
+63,114
+57% +$13.2M 0.01% 721
2021
Q1
$23.9M Buy
111,180
+8,347
+8% +$1.83M 0.01% 842
2020
Q4
$24.3M Buy
102,833
+50,900
+98% +$11.7M 0.01% 758
2020
Q3
$14.1M Buy
51,933
+40,423
+351% +$11.2M 0.01% 972
2020
Q2
$3.34M Sell
11,510
-3,811
-25% -$1.03M ﹤0.01% 2353
2020
Q1
$3.65M Buy
15,321
+6,495
+74% +$1.49M ﹤0.01% 1438
2019
Q4
$1.93M Sell
8,826
-5,392
-38% -$1.09M ﹤0.01% 1979
2019
Q3
$2.41M Buy
14,218
+3,697
+35% +$654K ﹤0.01% 1602
2019
Q2
$1.93M Sell
10,521
-3,507
-25% -$613K ﹤0.01% 1909
2019
Q1
$2.58M Buy
14,028
+7,785
+125% +$1.44M ﹤0.01% 1752
2018
Q4
$1.03M Sell
6,243
-30,459
-83% -$5.28M ﹤0.01% 2505
2018
Q3
$7.07M Sell
36,702
-17,580
-32% -$3.13M 0.01% 813
2018
Q2
$9.23M Buy
54,282
+33,885
+166% +$5.25M 0.02% 649
2018
Q1
$3.33M Buy
20,397
+14,581
+251% +$2.38M 0.01% 1312
2017
Q4
$872K Sell
5,816
-6,439
-53% -$953K ﹤0.01% 2505
2017
Q3
$1.86M Sell
12,255
-10,915
-47% -$1.64M 0.01% 1664
2017
Q2
$2.99M Sell
23,170
-1,536
-6% -$185K 0.01% 1133
2017
Q1
$2.7M Sell
24,706
-43,822
-64% -$3.86M 0.01% 1112
2016
Q4
$5.05M Buy
68,528
+62,217
+986% +$5.06M 0.02% 660
2016
Q3
$550K Sell
6,311
-9,089
-59% -$859K ﹤0.01% 2668
2016
Q2
$1.32M Sell
15,400
-11,617
-43% -$1M 0.01% 1680
2016
Q1
$2.15M Sell
27,017
-1,752
-6% -$158K 0.01% 1116
2015
Q4
$3.62M Buy
28,769
+6,662
+30% +$804K 0.02% 660
2015
Q3
$2.3M Sell
22,107
-24,139
-52% -$3.1M 0.01% 868
2015
Q2
$5.71M Buy
46,246
+39,221
+558% +$4.94M 0.04% 408
2015
Q1
$829K Sell
7,025
-790
-10% -$94.7K 0.01% 1540
2014
Q4
$928K Buy
7,815
+6,032
+338% +$679K 0.01% 1078
2014
Q3
$200K Sell
1,783
-9,239
-84% -$880K ﹤0.01% 2230
2014
Q2
$1.04M Sell
11,022
-1,010
-8% -$70.8K 0.01% 883
2014
Q1
$851K Buy
+12,032
New +$953K 0.01% 1090
2013
Q3
Sell
-12,609
Closed -$1.01M 3164
2013
Q2
$1.01M Buy
+12,609
New +$929K 0.02% 907

Other funds holding VRTX

Jane Street's VRTX Position: Q1 2026 in Review

Jane Street increased its Vertex Pharmaceuticals (VRTX) stake by 993% in Q1 2026, buying an estimated $52.1M and bringing the position to 122,946 shares worth $54.9M. The position accounts for 0.01% of the portfolio, ranked #990.

Jane Street first reported a position in VRTX in Q2 2013 and has held it in 49 quarters since. The position peaked at $142M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Jane Street held 122,946 shares of Vertex Pharmaceuticals worth $54.9M as of Q1 2026.
  • Jane Street bought 111,700 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.1M.
  • Vertex Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q1 2026, its #990 holding.
  • Jane Street first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • Jane Street's Vertex Pharmaceuticals position peaked at $142M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.